Upwards of 17 investors, including AbbVie, Eli Lilly, Alphabet, Merck & Co and Amgen, backed the neurodegenerative disease drug developer's series E round.
Alector, a US-based biotechnology developer focused on neurodegenerative diseases, secured $133m in series E funding yesterday from investors including GV, a corporate venturing vehicle for technology and internet conglomerate Alphabet.
Pharmaceutical companies AbbVie, Eli Lilly, Merck & Co and Amgen participated in the round through respective subsidiaries AbbVie Ventures, Lilly Asia Ventures, MRL Ventures and Amgen Ventures.
Dementia Discovery Fund, Deerfield Management, Federated Kaufmann Fund, Section 32, Euclidean Capital, Foresite Capital, New Leaf Venture Partners, Perceptive Advisors, Casdin Capital, Polaris…